| Primary |
| Multiple Sclerosis |
25.1% |
| Premedication |
14.4% |
| Asthma |
7.8% |
| Lymphoma |
6.8% |
| Prophylaxis |
4.9% |
| Rheumatoid Arthritis |
4.9% |
| Multiple Sclerosis Relapse |
3.8% |
| Ill-defined Disorder |
3.7% |
| Breast Cancer |
3.2% |
| Chemotherapy |
2.9% |
| Hypertension |
2.7% |
| Drug Use For Unknown Indication |
2.6% |
| Pain |
2.4% |
| Prophylaxis Against Renal Transplant Rejection |
2.4% |
| Interstitial Lung Disease |
2.2% |
| Nephrotic Syndrome |
2.2% |
| Non-hodgkin's Lymphoma |
2.2% |
| Hypersensitivity |
2.1% |
| Immunosuppression |
2.0% |
| General Anaesthesia |
1.8% |
|
| Urticaria |
11.5% |
| Rash |
7.1% |
| Thrombocytopenia |
7.1% |
| Vomiting |
5.8% |
| Osteonecrosis |
5.6% |
| Psychotic Disorder |
5.1% |
| Hypersensitivity |
4.9% |
| Anaphylactic Reaction |
4.7% |
| Liver Disorder |
4.5% |
| Malaise |
4.5% |
| Shock |
4.5% |
| Pain |
4.3% |
| Weight Increased |
4.3% |
| Dyspnoea |
4.1% |
| Tachycardia |
4.1% |
| Blood Glucose Increased |
3.8% |
| Pruritus |
3.8% |
| Tremor |
3.8% |
| Anaphylactic Shock |
3.4% |
| Hepatic Function Abnormal |
3.2% |
|
| Secondary |
| Product Used For Unknown Indication |
19.1% |
| Drug Use For Unknown Indication |
10.8% |
| Premedication |
9.0% |
| Asthma |
8.8% |
| Renal Transplant |
7.4% |
| Multiple Sclerosis |
5.9% |
| Prophylaxis |
5.4% |
| Rheumatoid Arthritis |
5.1% |
| Lymphoma |
3.4% |
| Immunosuppression |
3.2% |
| Non-hodgkin's Lymphoma |
3.0% |
| Chronic Obstructive Pulmonary Disease |
2.5% |
| T-cell Lymphoma |
2.3% |
| Pain |
2.2% |
| Multiple Sclerosis Relapse |
2.1% |
| Breast Cancer |
2.1% |
| Pneumonia |
2.0% |
| Hypersensitivity |
1.9% |
| Hypertension |
1.9% |
| Interstitial Lung Disease |
1.9% |
|
| Septic Shock |
11.3% |
| Thrombocytopenia |
9.1% |
| Vomiting |
8.7% |
| Weight Increased |
6.9% |
| Pyrexia |
5.7% |
| Osteonecrosis |
5.5% |
| Shock |
5.0% |
| Cytolytic Hepatitis |
4.6% |
| White Blood Cell Count Decreased |
4.6% |
| Sepsis |
4.5% |
| Respiratory Failure |
4.3% |
| Tendon Rupture |
3.9% |
| Weight Decreased |
3.9% |
| Shock Haemorrhagic |
3.6% |
| Anaphylactic Reaction |
3.3% |
| Diabetes Mellitus |
3.3% |
| Toxic Epidermal Necrolysis |
3.3% |
| Wheezing |
3.1% |
| Herpes Zoster |
2.7% |
| Multiple Sclerosis Relapse |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.8% |
| Drug Use For Unknown Indication |
19.3% |
| Premedication |
8.8% |
| Prophylaxis |
8.3% |
| Multiple Sclerosis |
5.9% |
| Renal Transplant |
5.2% |
| Hypertension |
3.3% |
| Pain |
3.2% |
| Crohn's Disease |
2.6% |
| Rheumatoid Arthritis |
2.3% |
| Infection Prophylaxis |
2.2% |
| Asthma |
2.1% |
| Breast Cancer |
2.0% |
| Constipation |
1.6% |
| Prophylaxis Against Transplant Rejection |
1.5% |
| Immunosuppression |
1.4% |
| Relapsing-remitting Multiple Sclerosis |
1.4% |
| Chronic Obstructive Pulmonary Disease |
1.4% |
| Gout |
1.4% |
| Pneumonia |
1.3% |
|
| Vomiting |
10.6% |
| Thrombocytopenia |
9.9% |
| Pyrexia |
6.4% |
| Pneumonia |
5.5% |
| Weight Decreased |
5.5% |
| Urinary Tract Infection |
4.9% |
| White Blood Cell Count Increased |
4.9% |
| Sepsis |
4.8% |
| Urticaria |
4.8% |
| White Blood Cell Count Decreased |
4.8% |
| Renal Failure |
4.5% |
| Respiratory Failure |
4.4% |
| Infusion Related Reaction |
4.3% |
| Weight Increased |
4.0% |
| Renal Failure Acute |
3.9% |
| Renal Impairment |
3.7% |
| Pain |
3.7% |
| Death |
3.4% |
| Wheezing |
3.1% |
| Tachycardia |
2.9% |
|
| Interacting |
| Interstitial Lung Disease |
14.4% |
| Rheumatoid Arthritis |
14.4% |
| Multiple Sclerosis |
11.0% |
| Drug Use For Unknown Indication |
10.2% |
| Hypertension |
9.3% |
| Respiratory Tract Infection |
5.1% |
| Unevaluable Event |
5.1% |
| Nephrotic Syndrome |
4.2% |
| Prostate Cancer |
4.2% |
| Angina Pectoris |
3.4% |
| Myalgia |
3.4% |
| Pollakiuria |
3.4% |
| Cryptosporidiosis Infection |
2.5% |
| Diabetes Mellitus |
2.5% |
| Bronchopulmonary Aspergillosis |
1.7% |
| Pneumonia |
1.7% |
| Product Used For Unknown Indication |
1.7% |
| Depression |
0.8% |
| Thyroid Disorder |
0.8% |
|
| Respiratory Failure |
21.4% |
| Liver Disorder |
14.3% |
| Drug Interaction |
10.7% |
| Gastrointestinal Perforation |
10.7% |
| Bradycardia |
7.1% |
| Hepatic Function Abnormal |
7.1% |
| Multiple Sclerosis Relapse |
7.1% |
| White Blood Cell Count Decreased |
7.1% |
| Anaemia |
3.6% |
| Electrocardiogram Qt Prolonged |
3.6% |
| Hypertensive Encephalopathy |
3.6% |
| Tibia Fracture |
3.6% |
|
